Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

A Canadian teen's breasts grew fourfold after receiving the Pfizer COVID-19 vaccine, raising concerns about a rare condition ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...

Pfizer (PFE) closed the most recent trading day at $26.91, moving -0.83% from the previous trading session. This change lagged the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...